John Gever

B cell-targeting drug could treat numerous other autoimmune diseases

And not even a very effective one

Autopsy data show massive abnormalities are common

Meta-analysis of over 200 randomized trials points to one winner for the short and medium terms

Phase III trial shows efficacy, but lacks comparison with other active treatments

It's getting harder to argue against these products as wonder drugs

Astonishing success in one patient who had exhausted all other medical therapies

More evidence for anti-inflammatory effect in addition to metabolic benefits

Online CBT Improves Mental Health in Rheumatology Patients

Lupus, RA Hit Pregnant Veterans Hard